SCHEDULE: ARK & Wood Boost Twist Bioscience Stake

ARK Investment Management and Catherine D. Wood have filed an Amendment No. 7 to their Schedule 13G, disclosing a combined beneficial ownership of 12.36% in Twist Bioscience Corp.

Summary

• ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 7 to their Schedule 13G regarding their ownership of Common Stock of Twist Bioscience Corp.
• The reporting persons collectively beneficially own 7,559,495 shares of Twist Bioscience Corp. Common Stock.
• This aggregate amount represents 12.36% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 7,091,113 shares and shared voting power over 136,132 shares.
• Catherine D. Wood holds shared voting power over 7,227,245 shares.
• ARK Investment Management LLC holds sole dispositive power over 7,559,495 shares.
• Catherine D. Wood holds shared dispositive power over 7,559,495 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as it confirms a significant and sustained investment by a prominent growth-focused fund, suggesting continued confidence in the issuer's long-term prospects.

Positives

• Prominent investment firm ARK Investment Management LLC and its CEO Catherine D. Wood maintain a significant stake, indicating continued conviction in Twist Bioscience Corp.
• The aggregate beneficial ownership of 12.36% represents a substantial position in the company, signaling strong institutional support.

Future Outlook

The filing does not provide forward-looking statements or guidance from Twist Bioscience Corp. It primarily details the beneficial ownership status of ARK Investment Management LLC and Catherine D. Wood.

Management Comments

• Kellen Carter, Chief Compliance Officer of ARK Investment Management LLC, certified that the information set forth in the statement is true, complete, and correct.
• Catherine D. Wood, Chief Executive Officer and Chief Investment Officer, certified that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that ARK's continued significant stake in Twist Bioscience Corp, a company operating in the synthetic biology and genomics space, aligns with ARK's investment thesis focused on disruptive innovation. This indicates a sustained belief in the long-term growth potential of the biotechnology sector and Twist Bioscience's position within it.

Related Party Transactions

• ARK Innovation ETF, a series of a Delaware statutory trust and a client of ARK Investment Management LLC, has an interest in the securities reported herein in excess of 5 percent.

Stakeholder Impact

• Shareholders may perceive the continued significant ownership by ARK Investment Management and Catherine D. Wood as a vote of confidence in the company's strategy and future prospects.

Key Dates

Recommendation

The filing indicates a sustained, substantial stake by ARK Investment Management and Catherine D. Wood in Twist Bioscience Corp. This continued conviction from a prominent growth investor suggests underlying belief in the company's long-term potential, warranting a hold position for investors who align with this growth thesis.

Keywords

Twist Bioscience, ARK Investment Management, Catherine D. Wood, Schedule 13G, beneficial ownership, common stock, biotechnology, genomics, institutional investment